

Efficient microwave-assisted synthetic protocols and *in silico* behaviour prediction of *per*-substituted β -cyclodextrins.

K. Martina^a, G. Cravotto^{a*}, M. Caporaso^a, L. Rinaldi^{a,b}, C. Villalonga-Barber^c and G. Ermondi^b

^a Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Torino (Italy), Fax +390116707657; Tel: +390116707684

E-mail: giancarlo.cravotto@unito.it.

^b Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, Torino, 10126.

^c Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48. Vas. Constantinou Ave., 11635 Athens, Greece.

Contents:

Fig. 1: ^1H -NMR of *per*-(6-benzylamino-6-deoxy)- β -CD (**2a**)

Fig. 2: ^{13}C -NMR of **2a**

Fig. 3: HMQC ^1H - ^{13}C spectrum of **2a**

Fig 4: MS (ESI) spectrum of **2a**

Fig. 5: ^1H -NMR of **2b**

Fig. 6: ^{13}C -NMR of *per*-(6-allylamino-6-deoxy)- β -CD (**2b**)

Fig. 7: HMQC ^1H - ^{13}C spectrum of **2b**

Fig 8: MS (ESI) spectrum of **2b**

Fig. 9: ^1H -NMR of *per*-(6-butylamino-6-deoxy)- β -CD (**2c**)

Fig. 10: ^{13}C -NMR of **2c**

Fig. 11: HMQC ^1H - ^{13}C spectrum of **2c**

Fig 12: MS (ESI) spectrum of **2c**

Fig. 13: ^1H -NMR of *per*-(6-anilino-6-deoxy)- β -CD (**2d**)

Fig. 14: ^{13}C -NMR of **2d**

Fig. 15: HMQC ^1H - ^{13}C spectrum of **2d**

Fig 16: MS (ESI) spectrum of **2d**

Fig. 17: ^1H -NMR of *per*-(6-(2-chlorobenzylamino)-6-deoxy)- β -CD (**2e**)

Fig. 18: ^{13}C -NMR of **2e**

Fig. 19: HMQC ^1H - ^{13}C spectrum of **2e**

Fig 20: MS (ESI) spectrum of **2e**

Fig. 21: ^1H -NMR of *per*-(6-phenylethylamino-6-deoxy)- β -CD (**2f**)

Fig. 22: ^{13}C -NMR of **2f**

Fig. 23: HMQC ^1H - ^{13}C spectrum of **2f**

Fig. 24: MS (ESI) spectrum of **2f**

Fig. 25: ^1H -NMR of *per*-(6-methyl piperazino-6-deoxy)- β -CD (**2g**)

Fig. 26: ^{13}C -NMR of **2g**

Fig. 27: HMQC ^1H - ^{13}C spectrum of **2g**

Fig. 28: MS (ESI) spectrum of **2g**

Fig. 29: ^1H -NMR of *per*-(6-morpholino-6-deoxy)- β -CD (**2h**)

Fig. 30: ^{13}C -NMR of **2h**

Fig. 31: HMQC ^1H - ^{13}C spectrum of **2h**

Fig. 32: MS (ESI) spectrum of **2h**

Fig. 33: ^1H -NMR of *per*-(6-tetrahydroisoquinolino-6-deoxy)- β -CD (**2i**)

Fig. 34: ^{13}C -NMR of **2i**

Fig. 35: HMQC ^1H - ^{13}C spectrum of **2i**

Fig. 36: MS (ESI) spectrum of **2i**

Fig. 37: ^1H -NMR of *per*-(6(3-phenylureido)-6-deoxy)- β -CD (**5a**)

Fig. 38: ^{13}C -NMR of **5a**

Fig. 39: HMQC ^1H - ^{13}C spectrum of **5a**

Fig. 40: MS (ESI) spectrum of **5a**

Fig. 41: ^1H -NMR of *per*-(6(3-cyclohexylureido)-6-deoxy)- β -CD (**5b**)

Fig. 42: ^{13}C -NMR of **5b**

Fig. 43: HMQC ^1H - ^{13}C spectrum of **5b**

Fig. 44: MS (ESI) spectrum of **5b**

Fig. 45: ^1H -NMR of *per*-(6(3-benzylthioureido)-6-deoxy)- β -CD (**6a**)

Fig. 46: ^{13}C -NMR of **6a**

Fig. 47: HMQC ^1H - ^{13}C spectrum of **6a**

Fig. 48: MS (ESI) spectrum of **6a**

Fig. 49: ^1H -NMR of *per*-(6(3-phenylethylthioureido)-6-deoxy)- β -CD (**6b**)

Fig. 50: ^{13}C -NMR of **6b**

Fig. 51: HMQC ^1H - ^{13}C spectrum of **6b**

Fig. 52: MS (ESI) spectrum of **6b**

Fig. 53: ^1H -NMR of *per*-(6(3-butylthioureido)-6-deoxy)- β -CD (**6c**)

Fig. 54: ^{13}C -NMR of **6c**

Fig. 55: HMQC ^1H - ^{13}C spectrum of **6c**

Fig 56: MS (ESI) spectrum of **6c**

Fig 57: Chemical structure of the substituents

Fig 58: PCA of the synthetized CD derivatives




Fig 1. ¹H-NMR of *per*-(6-benzylamino-6-deoxy)- β -CD (**2a**)




Fig 2. ^{13}C NMR of *per*-(6-benzylamino-6-deoxy)- β -CD (**2a**)




Fig 3. HMQC spectrum (300 MHz for ^1H - ^{13}C , in $\text{DMSO}-d_6$) of *per*-(6-benzylamino-6-deoxy)- β -CD (**2a**)




Fig 4. MS (ESI) spectrum of *per*-(6-benzylamino-6-deoxy)- β -CD (**2a**)




Fig 5. ^1H -NMR of *per*-(6-allylamino-6-deoxy)- β -CD (**2b**)




Fig 6. ^{13}C NMR of *per*-(6-allylamino-6-deoxy)- β -CD (**2b**)




Fig 7. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-allylamino-6-deoxy)- β -CD (**2b**)




Fig 8. MS (ESI) spectrum of *per*-(6-allylamino-6-deoxy)- β -CD (**2b**)




Fig 9. ¹H-NMR of *per*-(6-butylamino-6-deoxy)- β -CD (**2c**)




Fig 10. ¹³C-NMR of *per*-(6-butylamino-6-deoxy)- β -CD (**2c**)




Fig 11. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-butylamino-6-deoxy)- β -CD (**2c**)




Fig 12. MS (ESI) spectrum of *per*-(6-butylamino-6-deoxy)- β -CD (**2c**)




Fig 13. ¹H-NMR of *per*-(6-anilino-6-deoxy)- β -CD (**2d**)




Fig 14. ¹³C-NMR of *per*-(6-anilino-6-deoxy)- β -CD (**2d**)




Fig 15. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-anilino-6-deoxy)- β -CD (**2d**)




Fig 16. MS (ESI) spectrum of *per*-(6-anilino-6-deoxy)- β -CD (**2d**)




Fig 17. ^1H -NMR of *per*-(6-(2-chlorobenzylamino)-6-deoxy)- β -CD (**2e**)




Fig 18. ^{13}C -NMR of *per*-(6-(2-chlorobenzylamino)-6-deoxy)- β -CD (**2e**)




Fig 19. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-(2-chlorobenzylamino)-6-deoxy)- β -CD (**2e**)




Fig 20. ESI (MS) spectrum of *per*-(6-(2-chlorobenzylamino)-6-deoxy)- β -CD (**2e**)




Fig 21. ¹H-NMR of *per*-(6-phenylethylamino-6-deoxy)- β -CD (**2f**)




Fig. 22 ¹³C-NMR of *per*-(6-phenylethylamino-6-deoxy)- β -CD (**2f**)




Fig 23. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-phenylethylamino-6-deoxy)- β -CD (**2f**)




Fig 24. ESI (MS) spectrum of *per*-(6-phenylethylamino-6-deoxy)- β -CD (**2f**)




Fig 25. ¹H-NMR of *per*-(6-methyl piperazino-6-deoxy)- β -CD (**2g**)




Fig. 26. ¹³C-NMR of *per*-(6-methyl piperazino-6-deoxy)- β -CD (**2g**)




Fig 27. HMQC spectrum (300 MHz for ^1H - ^{13}C , in $\text{DMSO}-d_6$) of *per*-(6-methyl piperazino-6-deoxy)- β -CD (**2g**)




Fig 28. MS (ESI) spectrum of *per*-(6-methyl piperazino-6-deoxy)- β -CD (**2g**)




Fig 29. ¹H-NMR of *per*-(6-morpholino-6-deoxy)- β -CD (**2h**)




Fig. 30. ¹³C-NMR of *per*-(6-morpholino-6-deoxy)- β -CD (**2h**)




Fig 31. HMQC spectrum (300 MHz for ¹H-¹³C, in D₂O) of *per*-(6-morpholino-6-deoxy)- β -CD (**2h**)




Fig 32. MS (ESI) spectrum of *per*-(6-morpholino-6-deoxy)- β -CD (**2h**)




Fig 33. ¹H-NMR of *per*-(6-tetrahydroisoquinolino-6-deoxy)- β -CD (**2i**)




Fig 34. ¹³C NMR of *per*-(6-tetrahydroisoquinolino-6-deoxy)- β -CD (**2i**)




Fig 35. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6-tetrahydroisoquinolino-6-deoxy)- β -CD (**2i**)




Fig 36. MS (ESI) spectrum of **2i**




Fig 37. ¹H-NMR of *per*-(6(3-phenylureido)-6-deoxy)- β -CD (**5a**)




Fig 38. ¹³C NMR of *per*-(6(3-phenylureido)-6-deoxy)- β -CD (**5a**)




Fig 39. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6(3-phenylureido)-6-deoxy)- β -CD (**5a**)




Fig 40. MS (ESI) spectrum of *per*-(6(3-phenylureido)-6-deoxy)- β -CD (**5a**)




Fig 41. ¹H-NMR of *per*-(6(3-cyclohexylureido)-6-deoxy)- β -CD (**5b**)




Fig 42. ¹³C NMR of *per*-(6(3-cyclohexylureido)-6-deoxy)- β -CD (**5b**)




Fig 43. HMQC spectrum (300 MHz for ¹H-¹³C, in CDCl₃) of *per*-(6(3-cyclohexylureido)-6-deoxy)- β -CD (**5b**)




Fig 44. MS (ESI) spectrum of *per*-(6(3-cyclohexylureido)-6-deoxy)- β -CD (**5b**)




Fig 45. ¹H-NMR of *per*-(6(3-benzylthioureido)-6-deoxy)- β -CD (**6a**)




Fig 46. ¹³C NMR of *per*-(6(3-benzylthioureido)-6-deoxy)- β -CD (**6a**)




Fig 47. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6(3-benzylthioureido)-6-deoxy)- β -CD (**6a**)




Fig 48. MS (ESI) spectrum of *per*-(6(3-benzylthioureido)-6-deoxy)- β -CD (**6a**)




Fig 49. ¹H-NMR of *per*-(6(3-phenylethylthioureido)-6-deoxy)- β -CD (**6b**)




Fig 50. ¹³C NMR of *per*-(6(3-phenylethylthioureido)-6-deoxy)- β -CD (**6b**)




Fig 51. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6(3-phenylethylthioureido)-6-deoxy)- β -CD (**6b**)




Fig 52. MS (ESI) spectrum of *per*-(6(3-phenylethylthioureido)-6-deoxy)- β -CD (**6b**)




Fig 53. ¹H-NMR of *per*-(6(3-butylthioureido)-6-deoxy)- β -CD (**6c**)




Fig 54. ¹³C NMR of *per*-(6(3-butylthioureido)-6-deoxy)- β -CD (**6c**)




Fig 55. HMQC spectrum (300 MHz for ¹H-¹³C, in DMSO-*d*₆) of *per*-(6(3-butylthioureido)-6-deoxy)- β -CD (**6c**)




Fig 56. MS (ESI) spectrum of *per*-(6(3-butylthioureido)-6-deoxy)- β -CD (**6c**)




Fig 57. Chemical structure of the substituents




Fig. 58. PCA of the synthesized CD derivatives. VolSurf+ descriptors were calculated for low energy conformations of each CD, obtained as explained in the paper, and submitted to a PCA analysis. The score plot of the first two main PCs (in parenthesis the variance %) is reported. Each CD is shown with a different color and small rectangles with the same color represent the correspondent conformations. Such conformations can be grouped in the highlighted region of the score plot. The plot shows how CD derivatives can be clustered mainly on the basis of substituents properties.